Shots: Amgen to acquire all outstanding shares of Rodeo for a $55M upfront along with ~$666M in cash as contingent milestones The acquisition will strengthen Amgen’s inflammation portfolio with the […]readmore
Tags : Acquire
Shots: The NDA submission is based on the P-III ADVANCE study, pivotal P-IIb/III study, and the P-III LTS study for Atogepant in 2,500+ patients. The P-III ADVANCE study involves assessing […]readmore
Shots: Organon to acquire Alydia Health for up to $240M including $215M up front out of which $50 will be paid prior to the spinoff of Organon, $165 will be […]readmore
Shots: Immunai acquires the Dropprint Genomics and also expand its team with the hiring of new experts in immunology, single-cell technologies and machine learning The acquisition and the new hiring […]readmore
Shots: Grifols acquires the remaining 56% share of GigaGen for $80M. The acquisition will add GigaGen’s pipeline of recombinant polyclonal Abs, including GIGA-2050 and boost Grifol’s portfolio if I-O therapies […]readmore
Shots: Takeda exercised its option to acquire Maverick for up to $525M up front as well as development and regulatory milestones including Takeda’s current equity stake and Maverick debt. The […]readmore
Shots: Resolution to receive $550M in cash at closing and ~$145M following the achievement of certain milestones. The transaction is expected to close in Apr’2021 The acquisition will expand Agilent’s […]readmore
Shots: Amgen to acquire all of the outstanding shares of Five Prime for $38.00 /share in cash, representing an equity value of ~ $1.9B. The transaction is expected to close […]readmore
Shots: Boston Scientific to acquire the global surgical business of Lumenis for $1.07B as an up front in cash. The transaction is expected to be completed in H2’21 BPEA will […]readmore
Shots: Ipsen to receive 400,000 shares at closing and an additional 200,000 shares as milestones, $81.63M as development and regulatory milestones & $423.24M as commercial milestones along with royalties on […]readmore